Colorado-based Edgewise Therapeutics, a muscle disease-focused biopharma company, closed 23% lower after Wednesday’s trading.

Australian biotech major CSL Limited (ASX: CSL) subsidiary CSL Behring today announced that it has successfully concluded ...

With two new lawsuits, Eli Lilly (NYSE: LLY) has escalated its legal campaign against the makers of unauthorized versions of ...

US generic manufacturer Padagis has received clearance to extend the shelf life of its over-the-counter naloxone nasal spray ...

North Carolina, USA-based clinical-stage gene therapy company Atsena Therapeutics has announced the successful closing of an ...

Swiss pharma giant Novartis (NOVN: VX) today announced the US Food and Drug Administration (FDA) has granted accelerated ...

Pharmaceuticals will be exempt from the tariffs on imports to the USA that were announced by US President Donald Trump ...

US clinical-stage biotech Nurix Therapeutics (Nasdaq: NRIX) announced that Sanofi (Euronext: SAN) has exclusively licensed an ...

The European Medicines Agency has temporarily suspended enrollment and dosing in a Phase II trial of Sarepta Therapeutics' ...

Swiss pharma major Roche (ROG: SIX) said a higher-dose version of its top-selling multiple sclerosis drug Ocrevus ...

CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol ...

US biotech Artis BioSolutions has officially launched with the acquisition of Landmark Bio, a translational development and ...